Sustained Release Nifedipine Formulations: An Appraisal of their Current Uses and Prospective Roles in the Treatment of Hypertension, Ischaemic Heart Disease and Peripheral Vascular Disorders

Drugs

Volumn 41, Issue 5, 1991, Pages 737-779

  Murdoch, David ^a   Brogden, Rex N ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CAPTOPRIL; DILTIAZEM; DIURETIC AGENT; ENALAPRIL; ISRADIPINE; LISINOPRIL; NIFEDIPINE; NITRENDIPINE;

ANGINA PECTORIS; BLOOD PRESSURE; CLINICAL ARTICLE; DRUG MIXTURE; FLUSHING; HEADACHE; HEART RATE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PERIPHERAL VASCULAR DISEASE; PREGNANCY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; VERTIGO;

CORONARY DISEASE; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DRUG DESIGN; HUMAN; HYPERTENSION; NIFEDIPINE; VASCULAR DISEASES;

ANGINA;

EID: 0025727456     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199141050-00006     Document Type: Article

References (312)

1. Diabetogenic effects of nifedipine
2. Hepatic reactions to nifedipine
3. Renal effects of nifedipine in healthy normotensive volunteers: effects of dose, formulation, duration of treatment, and chlorothiazide coadministration
4. Effect of nifedipine on antipyrine and theophylline disposition
5. Nifedipine-induced acute psychosis
6. A randomised double-blind crossover study of isosorbide mononitrate and nifedipine retard in chronic stable angina
7. Nifedipine does not decrease insulin secretion
8. Atenolol and sustained release nifedipine alone and in combination in hypertension
9. 2+ -antagonist in hypertension patients in the absence and presence of beta-adrenergic-blockade
10. Acute and long-term hypotensive effects and plasma concentrations of nifedipine in patients with essential hypertension
11. Hypotensive action and increased plasma renin activity by calcium antagonist (nifedipine) in hypertensive patients
12. A randomised, double-blind therapeutic trial of enalapril versus slow-release nifedipine in mild to moderate essential hypertension
13. Randomized double-blind comparison of isosorbide dinitrate and nifedipine in variant angina pectoris
14. Effect of nifedipine on renal function of normal subjects and hypertensive patients with renal functional impairment
15. Nifedipine and coronary artery disease
16. Alcoholic-like liver lesions induced by nifedipine
17. Enalapril in hypertensive diabetics: a comparison with nifedipine retard
18. Acute antihypertensive effect and pharmacokinetics of a tablet preparation of nifedipine
19. 2 laser in the excision of gingival hyperplasia caused by nifedipine
20. Comprehensive analysis of the efficacy of nifedipine in esophageal motor disturbances causing angina-like chest pain and/or dysphagia (1977–1988)
21. Renal response to acute nifedipine administration in normotensive and hypertensive patients during normal and low sodium intake
22. Diabetogenic effects of nifedipine
23. Effect of nifedipine and captopril on plasma lipoproteins in hypertensive patients
24. Usefulness of nifedipine for myocardial ischemia and the nifedipine gastrointestinal therapeutic system
25. Plasma concentrations of nifedipine in patients with renal failure
26. Postischemic mechanical and vascular dysfunction (myocardial ’stunning’ and microvascular ’stunning’) and the effects of calcium-channel blockers on ischemia/reperfusion injury
27. Evaluation of the efficacy of slow-release nifedipine in systemic hypertension by ambulatory intraarterial blood pressure monitoring
28. Effectiveness, tolerance, and long-term compliance with nifedipine slow-release in hypertensive patients with concomitant and severe pathologies
29. A randomized double-blind parallel study assessing the efficacy of nifedipine gits vs. hydrochlorothiazide (HCTZ) in the management of mild to moderate hypertension in the elderly patient
30. Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure
31. Effect of nifedipine on metabolism of glucose and secretion of insulin in diabetic patients
32. Antihypertensive effectiveness of nifedipine gastrointestinal therapeutic system in the elderly
33. Nifedipine: variability in its kinetics and metabolism in man
34. Long-acting nifedipine in moderate and severe hypertensive patients with serious concomitant diseases
35. Nifedipine in the treatment of hypertension in systemic lupus erythematosus
36. Hypertensive crisis associated with nifedipine withdrawal
37. Kalzium-Antagonisten: Kennt man ein Absetz-Syndrom?
38. The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine
39. Slow release nifedipine plus atenolol in chronic stable angina pectoris
40. Hyperglycaemic effect of nifedipine
41. Effects of nifedipine, verapamil and diltiazem on renal function
42. The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus
43. Preoperative management of pheochromocytoma with the calcium-antagonist nifedipine
44. Renal effects of acute calcium blockade with nifedipine in hypertensive patients receiving beta-adrenoceptor-blocking drugs
45. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine
46. Nifedipine inhibits cholecystokinin-induced gallbladder contraction
47. Captopril versus nifedipine — a double blind study in aged hypertensive patient. Abstract
48. Sublingual nifedipine in the treatment of hypertensive lower esophageal sphincter: clinical and manometric results
49. The Nifedipine-Total Ischemia Awareness Program: a national survey of painful and painless myocardial ischemia including results of antiischemic therapy
50. Nifedipine as a second line antihypertensive drug in pregnancy
51. Ambulatory blood pressure monitoring in the comparison of atenolol, nifedipine and their combination
52. Acute and long-term effects of nifedipine on plasma renin activity and plasma catecholamines in controls and hypertensive patients before and after metoprolol
53. Effect of posture, hydralazine, and nifedipine on hemodynamics, ventilation, and gas exchange in patients with chronic obstructive pulmonary disease
54. Slow channel blockers
55. Nifedipine-induced vasodilation in patients with Raynaud’s phenomenon
56. Effects of calcium channel inhibitors upon the efficacy of common antiepileptic drugs
57. Atenolol plus nifedipine for mild to moderate systemic hypertension after fixed doses of either agent alone
58. Lymphocyte sensitisation in nifedipine-induced hepatitis
59. Myocardial ischaemia during daily life in patients with stable angina: its relation to symptoms and heart rate changes
60. Effects of nifedipine on glucose tolerance and insulin release in man
61. Nifedipine-induced renal dysfunction. Alterations in renal hemodynamics
62. Silent myocardial ischemia
63. Hypertension in the elderly: a study of a combination of atenolol and nifedipine
64. The antihypertensive efficacy of nifedipine alone and in combination in general practice
65. Calcium channel blockers. Potential medical benefits and side effects
66. Nifedipine: interaction with cimetidine not ranitidine
67. Drug reactions and interactions
68. Cyclosporin-nifedipine interaction
69. Slow-release nifedipine versus placebo in the treatment of arterial hypertension. A double-blind ergometric evaluation of cardiac workload
70. Acute renal failure during nifedipine therapy in a patient with congestive heart failure
71. Antihypertensive effects at rest and during exercise of a calcium blocker, nifedipine, alone and in combination with metoprolol
72. Exacerbation of asthmatic symptoms after cessation of nifedipine therapy
73. Renal hemodynamic effects of vasodilation with nifedipine and hydralazine in patients with heart failure
74. The natriuresis following oral administration of the calcium antagonists - nifedipine and nitrendipine
75. Rebound vasospasm after coronary revascularization in association with calcium antagonist withdrawal
76. Anti-ischemic effects of slow-release formulations of nifedipine, isosorbide-5-mononitrate and their combination in patients with coronary heart disease
77. Regulatory control of synonym drug bioavailability; bioinequivalency of nifedipine preparations
78. Nifedipine-induced alterations in serum quinidine concentrations
79. Pharmacokinetics of vincristine in cancer patients treated with nifedipine
80. Long-term treatment of hypertension in the elderly with a combination of atenolol and nifedipine
81. Effect of nifedipine on blood sugar, insulin and glucagon levels after an oral glucose load
82. Changes in left ventricular mass during a double-blind study with chlorthalidone and slow-release nifedipine
83. Differential effects of nifedipine and diltiazem on methacholine-induced bronchospasm in allergic asthma
84. Gingival hyperplasia associated with nifedipine
85. A double-blind cross-over study of nifedipine retard in patients with Raynaud’s phenomenon
86. Hemodynamic and renin responses to nifedipine in renovascular hypertension
87. Low-dose atenolol and nifedipine for the treatment of hypertension
88. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects
89. Regression of left ventricular hypertrophy during combined atenolol and nifedipine treatment
90. Multicenter comparison of the nifedipine gastrointestinal therapeutic system and long-acting propranolol in patients with mild to moderate systemic hypertension receiving diuretics. A preliminary experience
91. The nifedipine gastrointestinal therapeutic system in the treatment of hypertension
92. Effect of long-term treatment with slow-release nifedipine on glucose homeostasis in hypertensive-diabetic patients
93. Antihypertensive effectiveness of the nifedipine gastrointestinal therapeutic system
94. Nifedipine in unstable angina. A double-blind, randomized trial
95. Food increases the absorption of another retinoid and of prolonged-release nifedipine
96. A comparison of long acting nifedipine and enalapril in elderly hypertensives: a randomised, single-blind, cross-over study
97. Effect of nifedipine on glucose tolerance, serum insulin, and serum fructosamine in diabetic and nondiabetic patients
98. Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm
99. Impairment of insulin secretion in man by nifedipine
100. Antihypertensive and metabolic effects of long-term treatment with nifedipine (Adalat®)
101. Nifedipine and coronary artery disease
102. Effect of nifedipine on the development of coronary bypass graft stenoses in high-risk patients: a randomized, double-blind, placebo-controlled trial
103. Calcium channel blockers and the prevention of atherosclerosis
104. Dermatopharmacology: drugs around the corner
105. Painful edema, erythematous rash, and burning sensation due to nifedipine
106. An open study to evaluate the efficacy and tolerability of sustained-release nifedipine in the treatment of mild to moderate essential hypertension
107. Nitrendipine vs. long-acting nifedipine in mild, moderate and severe hypertension
108. Short and long-term efficacy of a calcium-antagonistic agent (nifedipine) combined with methyldopa in the treatment of severe hypertension
109. Development of immune complex nephritis during treatment with the calcium channel-blocking agent nifedipine
110. Nifedipine-pro-pranolol interaction: dependence of cardiovascular effects on plasma drug concentrations
111. Measurement of nifedipine in plasma by gas-liquid chromatography and electron-capture detection
112. Drugs, including alcohol, that act as risk factors for cataract, and possible protection against cataract by aspirin-like analgesics and cyclopenthiazide
113. A case of acute respiratory failure precipitated by long-acting nifedipine
114. Limitation of myocardial ischemic injury by nifedipine in patients with acute myocardial infarction evaluated by body surface mapping. Abstract
115. A double-blind randomized cross-over study of the efficacy and tolerability of nifedipine and nitrendipine in the treatment of mild to moderate hypertension
116. Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom
117. The effect of nifedipine on bronchial reactivity to inhaled histamine and methacholine: a comparative study in normal and asthmatic subjects
118. Spironolactone versus nifedipine in essential hypertension
119. Diabetogenic effect of nifedipine
120. Acute effects of the calcium antagonist, nifedipine, on blood pressure, pulse rate, and the renin-angiotensin-aldosterone system in patients with essential hypertension
121. Effect of food ingestion on nifedipine absorption and haemo-dynamic response
122. Regulation of the L-type calcium channel
123. Effects of nifedipine gits and atenolol monotherapy on serum lipids in mild to moderate hypertension
124. Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism
125. Nifedipine in the treatment of hypertension in blacks: a double-blind placebo-controlled trial in Nigerian hypertensives
126. Hemodynamic effects of nifedipine slow-release tablets in patients with essential hypertension
127. Slow release nifedipine and atenolol as initial treatment in blacks with malignant hypertension
128. The interaction between i.v. theophylline and chronic oral dosing with slow release nifedipine in volunteers
129. Acute hypotensive response to nifedipine added to prazosin in treatment of hypertension
130. Potentiation of nondepolarizing muscle relaxants by nifedipine during isoflurane anesthesia
131. Nifedipine in Raynaud’s phenomenon: relationship between immediate, short term and longterm effects
132. Evaluation of antianginal effect of nisoldipine (BAY k 5552) in patients with angina of effort using a treadmill exercise test
133. Possible coronary spasm rebound to abrupt nifedipine withdrawal. Correspondence
134. Long-term effects of nifedipine treatment on blood pressure, lipoproteins, apolipoproteins, and glycemic control in diabetic patients with hypertension
135. Plasma lipoprotein and apolipoprotein concentrations and glycemic control during short-term treatment with nifedipine in hypertensive patients with type II diabetes mellitus
136. Muscle cramps during treatment with nifedipine
137. Hemodynamic and reflex responses to acute and chronic antihypertensive therapy with the calcium entry blocker nifedipine
138. Ranitidin-Nifedipin Interaktion
139. Einfluss von Cimetidin und Ranitidin auf pharmakokinetik und antihypertensiven Effekt von Nifedipin
140. Ranitidine increases bioavailability of nifedipine. Abstract
141. The combined effect of nifedipine and sodium cromoglycate on the airway response to inhaled hypertonic saline in patients with bronchial asthma
142. Relapsing anaphylaxis to bee sting in a patient treated with a beta-blocker and Ca blocker
143. Rate of increase in the plasma concentration of nifedipine as a major determinant of its haemodynamic effects in humans
144. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man
145. Nifedipine: kinetics and dynamics in healthy subjects
146. Liquid Chromatographic determination of nifedipine in plasma and of its main metabolite in urine
147. Identification of nifedipine metabolites and their determination by gas chromatography
148. The bioavailability of oral nifedipine formulations: a statistical and simulation approach
149. Nifedipine gastrointestinal therapeutic system in the treatment of hypertension: results of a multicenter trial
150. The dependence of the cardiac effects of nifedipine on the responses of the peripheral vascular system
151. Acute intestinal occlusion and calcium antagonists
152. Relationship between the antihypertensive effect and steady state plasma concentration of nifedipine given alone or in combination with a beta adrenoceptor blocking agent
153. Comparison of acute effects of nifedipine in normotensive and hypertensive man
154. Acute and chronic effects of nifedipine in arterial hypertension
155. Effect of nifedipine on plasma renin, aldosterone and catecholamines in arterial hypertension
156. Gingival hyperplasia associated with nifedipine therapy
157. The effect of nifedipine on plasma lipids in patients with essential hypertension
158. Nifedipine in congestive heart failure: effects on resting and exercise hemodynamics and regional blood flow
159. Comparison of cardiovascular, renal, and humoral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects
160. Rebound of vasospastic angina after cessation of long-term treatment with nifedipine
161. The kinetics of nifedipine release from porous hydrophilic matrices and the pharmacokinetics in man
162. Antihypertensive efficacy of nifedipine in a novel delivery system: correlation with serum nifedipine levels
163. Nifedipine gastrointestinal therapeutic system (NGITS) in patients with mild essential hypertension: therapeutic effects of a novel delivery system
164. Adverse reactions to calcium antagonists
165. Nifedipine and coronary artery disease
166. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT)
167. Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the Intact study (International Nifedipine Trial on Antiatherosclerotic Therapy)
168. 2+ -entry blockers on hemodynamics and coronary blood flow, and its importance for the treatment of angina pectoris
169. Antiatherosclerotic activity of nifedipine in primates. Abstract
170. Comparison of felodipine with nifedipine as additions to metoprolol in the treatment of hypertension
171. Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris
172. Muscle cramps during treatment with nifedipine
173. Felodipine compared to nifedipine in hypertension
174. Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability
175. Low-dose nifedipine retard in elderly hypertensive patients
176. Nifedipine in the treatment of Raynaud’s phenomenon. Evidence for inhibition of platelet activation
177. Unstable angina precipitated by nifedipine
178. Long-term captopril treatment in elderly hypertensive patients
179. General practice data derived tolerability assessment of antihypertensive drugs
180. Development of tolerance to nifedipine in patients with stable angina pectoris
181. Relaxation of potassium chloride-induced contractions by amlodipine and its interaction with the 1,4-dihydropyridine-binding site in pig coronary artery
182. Comparison of the efficacy and long-term tolerability of a combination of atenolol and nifedipine with atenolol alone in the treatment of hypertension
183. The effect of nifedipine on arterial pressure and reflex cardiac control
184. Nifedipine and nocturia
185. Effect of chronic nifedipine in patients inadequately controlled by a converting enzyme inhibitor and a diuretic
186. Consistent blood pressure reduction without loss of diurnal variability with once-daily nifedipine GITS treatment
187. The antihypertensive effects of nifedipine (GITS) in mild to moderate hypertension
188. Role of nifedipine in treatment of hypertension
189. Comparative pharmacokinetics and antihypertensive effects of the nifedipine tablet and capsule
190. Calcium antagonist withdrawal syndrome
191. Effect of nifedipine retard tablets in hypertension: evaluation using a noninvasive portable automatic sphygmomanometer and a new method of assessment
192. Calcium antagonist withdrawal syndrome
193. Cerebral ischaemia after nifedipine treatment
194. Influence of quinidine on nifedipine plasma pharmacokinetics
195. Nifedipine as an antihypertensive drug in patients with renal failure — pharmacokinetics and effects
196. Efficacy of nifedipine GITS vs hydrochlorthiazide in the management of moderate hypertension in the black hypertensive
197. Combination chemotherapy with the calcium channel blocker nifedipine and cisplatin
198. Nifedipine-induced nonthrombocytopenic purpura
199. Use of nifedipine in the management of systemic hypertension in Nigerian patients
200. Pharmacokinetics and bioavailability of three different galenic nifedipine preparations
201. Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers
202. A comparison of verapamil and nifedipine on quality of life
203. Long-term nifedipine treatment and glucose homeostasis in hypertensive patients
204. Haemodynamic parameters in hypertensive patients: changes induced by lacidipine and nifedipine
205. Hemodynamic and endocrine effects of acute and chronic administration of nifedipine
206. Effects of nifedipine on insulin secretion and plasma lipids in hypertensive patients
207. Gas chromatographic-mass spectrometric analysis of plasma nifedipine
208. Combined acebutolol/ nifedipine therapy in patients with chronic coronary artery disease: additional improvement of ischaemic-induced left ventricular dysfunction
209. Cardiac and hemodynamic adjustments to rapid and sustained blood pressure reduction
210. Comparison of the antianginal efficacy of four calcium antagonists and propranolol in stable angina pectoris
211. Transient retinal ischaemia reduced by nifedipine
212. Consecutive cardiac arrests on induction of anesthesia associated with nifedipine-induced carotid sinus hypersensitivity
213. Comparison of nifedipine and captopril as third-line agents in hypertensive patients uncontrolled with beta-blocker and diuretic therapy
214. A double-blind, placebo-controlled, crossover trial to investigate the additive hypotensive effect of a diuretic (mefruside) to that produced by nifedipine
215. Ni-fedipine-alcohol interaction
216. How important is a history of chest pain in determining the degree of ischaemia in patients with angina pectoris?
217. Pharmacokinetics and metabolism of nifedipine
218. Gingival hyperplasia caused by nifedipine - a preliminary report
219. Effect of nifedipine on renal function in patients with essential hypertension
220. A fixed combination of atenolol 50mg and nifedipine 20mg in the long term treatment of hypertension
221. Effect of food on nifedipine pharmacokinetics
222. Calcium metabolism and the renin-aldosterone system determine the acute blood pressure response to calcium channel blockade
223. Exfoliative dermatitis due to nifedipine
224. Effects of nifedipine on myocardial perfusion during exercise in chronic stable angina pectoris
225. Lisinopril in essential hypertension: a six month comparative study with nifedipine
226. Oral nifedipine in the treatment of noncardiac chest pain in patients with the nutcracker esophagus
227. The influence of food on the pharmacokinetics of ‘biphasic’ nifedipine at steady state in normal subjects
228. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine
229. Effects of nifedipine on resistance vessels, arteries and veins in man
230. Tolerability of sustained release nifedipine
231. Efficacy of nifedipine and nicardipine in hypertensive patients at rest and during stress testing
232. Lymphocyte sensitisation in nifedipine-induced hepatitis
233. Nifedipine and platelets in preeclampsia
234. The treatment of chilblains with nifedipine: the results of a pilot study, a double-blind placebo-controlled randomized study and a long-term open trial
235. Pharmacokinetics and acute side-effects of nifedipine given as slow-release tablets or liquid-filled capsules
236. Captopril and nifedipine interactions in the treatment of essential hypertensives: a crossover study
237. The effect of nifedipine and nicardipine on glucose tolerance, insulin and C-peptide
238. Effect of nifedipine on serum lipids, lipoproteins, and apolipoproteins in patients with essential hypertension
239. Paradoxical angina after nifedipine: angiographic documentation
240. Acute natriuretic effect of nifedipine in elderly males with essential hypertension
241. Nifedipine monotherapy in the hypertensive elderly: a placebo-controlled clinical trial
242. Antihypertensive and metabolic effects of diltiazem and nifedipine
243. Calcium antagonists: review and perspective on mechanism of action
244. Oral nifedipine in the treatment of hypertensive urgency: cerebrovascular accident following a single dose
245. Nifedipine nephritis. Correspondence
246. Antiatherosclerotic effects of nifedipine and nitrendipine in rats with experimental atherosclerosis
247. Adverse effects of sublingual nifedipine in acute myocardial infarction
248. Captopril and nifedipine in combination for moderate to severe essential hypertension
249. The mechanism of action of calcium antagonists relative to their clinical applications
250. Effet de l’hemodialyse sur les taux plasmatiques de nifedipine
251. Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: the Norwegian nifedipine multicenter trial
252. Ranitidine and cimetidine; drug interactions with single dose and steady-state nifedipine administration
253. Effect of nifedipine on serum theophylline concentrations and asthma control
254. Androgen metabolism in gingival hyperplasia induced by nifedipine and cyclosporin
255. Efficacy and tolerability of isradipine and sustained release nifedipine in the management of hypertension
256. Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders
257. The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease: a review
258. Nifedipine in continuous ambulatory peritoneal dialysis
259. Efficacy and tolerability of atenolol, nifedipine and their combination in the management of hypertension
260. Nifedipine in the treatment of hypertension in the elderly
261. Efficacy of nifedipine therapy in patients with refractory angina pectoris: significance of the presence of coronary vasospasm
262. Nifedipine and alpha-adrenergic blockade
263. Double-blind, placebo-controlled trial of twice-daily nifedipine as a step-2 agent in mild essential hypertension
264. Nifedipine gastrointestinal therapeutic system
265. Pharmacokinetic studies of nifedipine tablet. Correlation with antihypertensive effects
266. Effectiveness of long-acting nifedipine in pheochromocytoma
267. Nifedipine therapy in angina pectoris: evaluation of safety and side effects
268. The beneficial influence of nifedipine on the regression of cholesterol-induced atherosclerosis in rabbits. Abstract
269. Efficacy and tolerability of a new once daily nifedipine formulation in mild to moderate essential hypertension
270. The role of nifedipine therapy in achalasia: results of a randomized, doubleblind, placebo-controlled study
271. Calcium antagonists in atherosclerosis: a review and commentary
272. Effect of food on nifedipine sustained-release preparation
273. Nifedipine and coronary artery disease
274. Once-daily therapy for angina pectoris with nifedipine gastrointestinal therapeutic system. Dosing and clinical efficacy
275. Pharmacokinetic and pharmacodynamic interactions between nifedipine and propranolol or betaxolol
276. Nitrates and calcium antagonists for silent myocardial ischemia
277. Vascular effects of calcium antagonists: implications for hypertension and other risk factors for coronary heart disease
278. Comparison of antianginal efficacies and exercise hemodynamic effects of nifedipine and diltiazem in stable angina pectoris
279. Clinical and Theological effects of nifedipine in Raynaud’s phenomenon
280. The first pass metabolism of nifedipine in man
281. The effects of intravenous and oral nifedipine on ex vivo platelet function
282. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis
283. Vasodilation in the vascular bed of skeletal muscle after intravenous nifedipine in normotensives and hypertensives
284. Antiatherogenic properties of calcium antagonists
285. Calcium antagonists as firstline antihypertensive agents: a placebo-controlled, comparative trial of isradipine and nifedipine
286. A dose finding study of the combination of atenolol and nifedipine in hypertension
287. Slow-release nifedipine as a single or additional agent in the treatment of essential hypertension — a placebo-controlled crossover study
288. Glycaemic control and exercise tolerance in hypertensive insulin-treated diabetes during nifedipine therapy
289. Lisinopril versus slow-release nifedipine in the treatment of mild to moderate hypertension: a multicentre study
290. Decreased rectal body temperature induced by different vasodilatory drugs
291. Long-acting nifedipine versus metoprolol as monotherapy for essential hypertension. A randomized, controlled crossover study
292. Ischémie ECG changes with initial nifedipine therapy of severe hypertension. Correspondence
293. Treatment of hypertensive pregnant patients with the long-acting preparation of nifedipine
294. Clinical effects of intravenous nifedipine on renal function
295. Effect of nifedipine on the contractile responses of human colonic muscle
296. Nifedipine-induced gingival hyperplasia: case reports and literature review
297. Comparison of nifedipine and propranolol used in combination with diuretics for the treatment of hypertension
298. Nifedipine, but not propranolol, improves left ventricular systolic and diastolic function in patients with hypertension
299. Pharmacokinetic interaction between nifedipine and propranolol